Chow Christopher Y C, Lie Erich Ferdiansyah, Wu Cheng-Hsun, Chow Louis W C
UNIMED Medical Institute, Hong Kong, Hong Kong SAR, China.
Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan.
Front Oncol. 2022 Oct 31;12:964824. doi: 10.3389/fonc.2022.964824. eCollection 2022.
The current clinical management model of HER2-positive breast cancers is commonly based on guidelines, which in turn are based on the design and outcome of clinical trials. While this model is useful to most practicing clinicians, the treatment outcome of individual patient is not certain at the start of treatment. As the understanding of the translational research of carcinogenesis and the related changes in cancer genetics and tumor microenvironment during treatment is critical in the selection of right choice of treatment to maximize the successful clinical outcome for the patient, this review article intends to discuss the latest developments in the genetic and molecular mechanisms of cancer progression and treatment resistance, and how they influence the planning of the treatment strategies of HER2-positive breast cancers.
目前HER2阳性乳腺癌的临床管理模式通常基于指南，而这些指南又基于临床试验的设计和结果。虽然这种模式对大多数执业临床医生有用，但在治疗开始时，个体患者的治疗结果并不确定。由于了解致癌作用的转化研究以及治疗期间癌症遗传学和肿瘤微环境的相关变化对于选择正确的治疗方案以最大限度地提高患者的临床成功结果至关重要，本文献综述旨在讨论癌症进展和治疗耐药的遗传和分子机制的最新进展，以及它们如何影响HER2阳性乳腺癌治疗策略的规划。
